We Work for Health | Washington

11/28/2025

"Europe’s retreat from biomedical innovation did not occur in a vacuum, and neither would America’s. As the West throttles its science, China is racing ahead."

https://dcjournal.com/america-cant-win-by-copying-europes-failures/

11/26/2025

"Supporters bill as a way to cut costs. In reality, it would import Europe’s system of government-set prices, and with it the predictable consequences: fewer available treatments, longer waits and stalled medical innovation."

https://www.thewellnews.com/opinions/most-favored-nation-drug-pricing-fails-patients-and-their-caregivers/

11/25/2025

"Price controls simply do not work. They are, in reality, counterproductive as a means of controlling costs. It is basic economics."

https://defenseopinion.com/price-controls-on-pharmaceuticals-benefit-u-s-military-competitor/1079/

11/21/2025

"If administration officials fail to make this distinction — and cap U.S. drug prices at the artificially low levels set overseas — the results could be catastrophic for our collective health and our economy."

won't work for the U.S.: https://www.chicagotribune.com/2025/11/07/opinion-donald-trump-drug-price-controls-astrazeneca-pfizer/

11/19/2025

Today, the U.S. Senate Aging Committee hearing on medicines will demonstrate how crucial it is to keep the U.S. a global leader in biopharma.

Biopharma investments boost our economy and leadership. Read more in this We Work for Health blog:

America's biopharmaceutical sector is delivering unprecedented investment in domestic innovation and manufacturing capacity. In 2025 alone, life sciences companies have committed over $425 billion in new investments to bolster research and development, expand manufacturing, and create jobs across th...

11/17/2025

Biopharma companies have made major U.S. investments this year. Progress may stall without policy in place.

Wednesday, the U.S. Senate Aging Committee will examine how to keep investments on track. 's Biopharma Investment Watch is tracking in real time:

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines.

11/14/2025

"Since the Affordable Care Act was fully implemented, the average premium for an ACA marketplace plan has doubled, and the average deductible for a Silver plan has increased by 92%. Every year, families pay more, yet the coverage often feels thinner."

https://healthcareuncovered.substack.com/p/where-do-our-health-insurance-premiums?utm_source=post-email-title&publication_id=255152&post_id=178118938&utm_campaign=email-post-title&isFreemail=true&r=18befa&triedRedirect=true&utm_medium=email

11/12/2025

"Nearly two-thirds of Illinois residents struggle to afford healthcare...But adopting foreign price-setting models that inadvertently restrict access to care is not the solution."

doesn't work for patients or providers:

Commentary: Lowering drug costs is important and an issue we must address as a nation, but the solution is not as simple as that proposed.

11/10/2025

"From university research labs to startup incubators, strong intellectual property protections allow scientists and entrepreneurs to turn breakthroughs into treatments and therapies that save lives in Tennessee and beyond."

Intellectual property isn't just a legal concept, it's a tangible driver that delivers innovation in Tennessee's health care sector.

11/07/2025

: Over $425 billion has already been invested in U.S. biopharma infrastructure in 2025.

We're just getting started: We Work for Health is tracking every commitment as they continue to grow.

We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines.

11/05/2025

"Some of our largest and wealthiest hospital systems are reaping millions of dollars from marking up discounted drugs meant for our underserved ."

isn't working as intended for patients: https://www.chicagotribune.com/2025/10/24/opinion-chicago-hospital-drug-price-aid-university-of-chicago-medicine-rush-medical-center/

11/03/2025

"When PDABs prioritize financial considerations over the reality of what a patient needs in that moment, they create artificial barriers that disrupt care. Healthcare should respond to patient needs—not the other way around."

https://www.healthaffairs.org/sponsored-content/national-minority-quality-forum/state-prescription-drug-affordability-boards-when-cost-takes-precedence-over-patient-health